The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
The use of procalcitonin testing for sepsis management is highest in the US
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Total investment envisaged in this project stands at up to Rs 70 crore
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Subscribe To Our Newsletter & Stay Updated
